In a significant move for investors, Charles River Laboratories International, Inc. (CRL) recently received an “Overweight” rating from Ricky Goldwasser of Morgan Stanley. Announced on June 17, 2026, this upgrade suggests a favorable outlook, especially with a price target set at $220, indicating substantial upside from the current trading level of $184.79.
Recent Price Action
Charles River Laboratories’ stock has exhibited volatility in recent trading sessions, closing at $184.79, just over $5 higher than the previous day’s close, reflecting a gain of approximately 2.76%. This performance comes amid a notably dynamic trading environment, as evidenced by the company’s beta of 1.449, which indicates higher volatility than the market. Over the last week, the stock has fluctuated significantly, with a high of $208.13 and a low of $180.00, leading to a weekly volatility metric of 4.33%. While the stock’s 52-week high stands at $208.13, it is important to note its 52-week low of $91.01, showcasing considerable recovery within the past year. With a market capitalization of approximately $9.15 billion and a trading volume of 245,464—well below its average volume of 856,996—investors are cautiously optimistic about the stock’s current trends.
[chart type=’price’ value=’CRL’]
Historical Performance
Charles River Laboratories has delivered commendable returns across various time frames, reinforcing investor confidence. Over the past 30 days, the stock has seen an impressive gain of 11.33%, while quarterly performance has jumped by 22.22%. These figures are reflective of a broader market recovering from initial headwinds, which makes the annual performance of 31.6% particularly striking. Monthly volatility has held steady at 3.1%, despite a spike in weekly volatility, indicating resilience in its performance amidst market fluctuations. The average volume over the past 10 days has been 670,134 shares, indicating a healthy interest from investors looking to capitalize on recent developments.
[chart type=’performance’ value=’CRL’]
Earnings Analysis
In an encouraging earnings report released on May 7, 2026, Charles River Laboratories reported earnings per share (EPS) of $2.06, surpassing analysts’ expectations of $1.96 by 5.1%. This positive surprise builds on the prior quarter’s performance where the company posted an EPS of $2.39 against an estimate of $2.33, leading to a surprise of 2.58%. This consistent ability to exceed earnings estimates suggests a robust operational performance and may cue investors to the company’s earnings quality and predictability moving forward.
[chart type=’income-bar-chart’ value=’CRL’]
Consensus Ratings
The consensus among analysts over the past 90 days indicates a solid backing for Charles River Laboratories, with six analysts providing estimates: five rate the stock as a “Buy,” and one as a “Hold.” The average price target stands at approximately $208.17, with a high target aligning with Morgan Stanley’s $220. This collection of ratings highlights both optimism and a strong belief in the company’s potential for growth. Notably, there are no “Sell” ratings, emphasizing a broadly positive sentiment.
[chart type=’analyst-ratings’ value=’CRL’]
Stock Grading and Fundamental View
Charles River Laboratories holds a Stocks Telegraph Score (ST Score) of 41, a critical indicator of its overall health and investment potential. This score reflects the company’s strong fundamentals, including stable earnings surprises and robust growth prospects in the life sciences sector. Investors may view the ST Score as a sign of its competitive positioning and capability to innovate within its industry.
[chart type=’st-cards’ value=’CRL’]
Conclusion
For investors considering Charles River Laboratories International, Inc. (CRL), the stock presents an intriguing opportunity, particularly for those inclined toward long-term growth investments. The recent upgrade to an “Overweight” rating suggests confidence in the company’s trajectory, backed by solid financial performance, favorable analyst sentiment, and an appealing valuation compared to its price targets. However, potential investors should also be mindful of market volatility and inherent risks associated with equity investments in the biopharmaceutical sector. As such, CRL warrants close attention from both growth-focused and risk-aware investors looking for exposure to innovative segments of the healthcare market.